Innovent Biologics, Inc. (OTCMKTS:IVBXF – Get Free Report) was down 0.2% during mid-day trading on Thursday . The company traded as low as $4.64 and last traded at $4.64. Approximately 108 shares were traded during trading, a decline of 99% from the average daily volume of 8,415 shares. The stock had previously closed at $4.65.
Innovent Biologics Stock Performance
The stock’s fifty day moving average price is $4.47 and its 200-day moving average price is $5.03.
About Innovent Biologics
Innovent Biologics, Inc, a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor.
Featured Stories
- Five stocks we like better than Innovent Biologics
- 3 Small Caps With Big Return Potential
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- 3 Monster Growth Stocks to Buy Now
- DuPont’s Electronics Spinoff: The Start of Something Big
- Roth IRA Calculator: Calculate Your Potential Returns
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
